Deals this week: Dilon Technologies, Pfizer, Merck

17 November 2016 (Last Updated November 17th, 2016 18:30)

Medical imaging products provider, Dilon Technologies, has received exclusive rights to distribute GE Healthcare's Discovery NM750b molecular breast imaging system in North America. The breast imaging system detects a broad range of breast-related conditions including cancer in the early stages.

Medical imaging products provider, Dilon Technologies, has received exclusive rights to distribute GE Healthcare's Discovery NM750b molecular breast imaging system in North America. The breast imaging system detects a broad range of breast-related conditions including cancer in the early stages.

Through the agreement, Dilon will be able to offer a complete range of BSGI / MBI solutions through its established channels.

Pfizer intends to raise gross proceeds of $1.75bn through a public offering of 3% notes due 2026. The interest on the notes will be payable every six months.

Concurrently, the company has announced public offering of 1.7% notes due 2019, to raise gross proceeds of $1bn, 2.2% notes due 2021, to raise gross proceeds of $1bn, 4% notes due 2036, to raise $1bn, and 4.125% notes due 2046, to raise $1.25bn.

Together, the company will raise $6bn, which will be used to purchase tender notes and to redeem any of the remained tender notes, and for general corporate purposes.

With an aim to develop novel rapid diagnostics and informatics tools that help fight antimicrobial resistance, Merck and OpGen have signed a new research agreement.

Pursuant to the agreement, Merck will provide OpGen access to its archive of bacterial pathogens, while OpGen will continue developing rapid DNA tests and a genomic knowledgebase of antibiotic-resistant pathogens. The knowledgebase will help predict antibiotic susceptibility based on test results.

A digital health company, US TrustedCare has collaborated with a semi-conductor intellectual property company, Arm Ltd, to develop new medical devices for accountable healthcare sector and for patients with chronic conditions.

"The knowledgebase will help predict antibiotic susceptibility based on test results."

The companies will collaborate to develop firmware, software technologies and active pharmaceutical ingredients (APIs) and will also integrate wearable and medical devices for accountable care.

To raise gross proceeds of $40m, Invitae Corporation has announced an offering of underwritten public shares of its common stock with a 30-day option for underwriters to purchase additional shares worth up to $6m.

The proceeds from the offering will be used to fund working capital, general corporate purposes, to acquire or invest in complementary businesses, for short and intermediate-term investments and the like.